| Identification | Back Directory | [Name]
CEP-40125 RXDX-107 | [CAS]
1456608-94-8 | [Synonyms]
RXDX-107
CEP-40125
CEP40125,CEP 40125
CEP-40125 RXDX-107
1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-, dodecyl ester | [Molecular Formula]
C28H45Cl2N3O2 | [MDL Number]
MFCD32204616 | [MOL File]
1456608-94-8.mol | [Molecular Weight]
526.58 |
| Hazard Information | Back Directory | [Uses]
CEP-40125 (RXDX-107) is a modified form of Bendamustine (HY-13567), a DNA cross-linking agent that may cause DNA damage and cell apoptosis. CEP-40125 (RXDX-107) is formed by encapsulating the alkyl ester form of Bendamustine in human serum albumin[1][2]. | [References]
[1] Pharmaceutical prodrugs and methods of their preparation and use. WO2018013783.
[2] Croasdell G. The 34th Annual JP Morgan Healthcare Conference. San Francisco, California, USA-January 11-14, 2016[J]. Drugs of the Future, 2016, 41(1). |
|
|